zimeldine and Cardiovascular-Diseases

zimeldine has been researched along with Cardiovascular-Diseases* in 3 studies

Reviews

1 review(s) available for zimeldine and Cardiovascular-Diseases

ArticleYear
The side effect profile and safety of fluoxetine.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2

    The side effect profile and safety of fluoxetine are reviewed. Side effects reported more frequently with fluoxetine than with tricyclic antidepressants are nausea, nervousness, and insomnia. Anticholinergic side effects are reported less often with fluoxetine. Analysis of adverse experiences leading to discontinuations suggests that this drug has very few serious side effects. There is no evidence that fluoxetine produces a flu-like syndrome or neuropathy similar to that seen with zimelidine. It does not appear to cause phospholipidosis in humans. Fluoxetine appears to have no epileptogenic potential except at extremely high doses. It is usually well tolerated in overdoses.

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Female; Fluoxetine; Humans; Influenza, Human; Lipidoses; Male; Middle Aged; Nausea; Nervous System Diseases; Patient Dropouts; Phospholipids; Placebos; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Initiation and Maintenance Disorders; Suicide, Attempted; Vision Disorders; Zimeldine

1985

Trials

1 trial(s) available for zimeldine and Cardiovascular-Diseases

ArticleYear
The side effect profile and safety of fluoxetine.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2

    The side effect profile and safety of fluoxetine are reviewed. Side effects reported more frequently with fluoxetine than with tricyclic antidepressants are nausea, nervousness, and insomnia. Anticholinergic side effects are reported less often with fluoxetine. Analysis of adverse experiences leading to discontinuations suggests that this drug has very few serious side effects. There is no evidence that fluoxetine produces a flu-like syndrome or neuropathy similar to that seen with zimelidine. It does not appear to cause phospholipidosis in humans. Fluoxetine appears to have no epileptogenic potential except at extremely high doses. It is usually well tolerated in overdoses.

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Female; Fluoxetine; Humans; Influenza, Human; Lipidoses; Male; Middle Aged; Nausea; Nervous System Diseases; Patient Dropouts; Phospholipids; Placebos; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Initiation and Maintenance Disorders; Suicide, Attempted; Vision Disorders; Zimeldine

1985

Other Studies

2 other study(ies) available for zimeldine and Cardiovascular-Diseases

ArticleYear
Hospital outcomes in major teaching, minor teaching, and nonteaching hospitals in New York state.
    The American journal of medicine, 2002, Volume: 112, Issue:4

    The possible benefit that hospital teaching status may confer in the care of patients with cardiovascular disease is unknown. Our purpose was to determine the effect of hospital teaching status on in-hospital mortality, use of invasive procedures, length of stay, and charges in patients with myocardial infarction, heart failure, or stroke.. We analyzed a New York State hospital administrative database containing information on 388 964 consecutive patients who had been admitted with heart failure (n = 173 799), myocardial infarction (n = 121 209), or stroke (n = 93 956) from 1993 to 1995. We classified the 248 participating acute care hospitals by teaching status (major, minor, nonteaching). The primary outcomes were standardized in-hospital mortality ratios, defined as the ratio of observed to predicted mortality.. Standardized in-hospital mortality ratios were significantly lower in major teaching hospitals (0.976 for heart failure, 0.945 for myocardial infarction, 0.958 for stroke) than in nonteaching hospitals (1.01 for heart failure, 1.01 for myocardial infarction, 0.995 for stroke). Standardized in-hospital mortality ratios were significantly higher for patients with stroke (1.06) but not heart failure (1.0) or myocardial infarction (1.06) in minor teaching hospitals than in nonteaching hospitals. Compared with nonteaching hospitals, use of invasive cardiac procedures and adjusted hospital charges were significantly greater in major and minor teaching hospitals for all three conditions. The adjusted length of stay was also shorter for myocardial infarction in major teaching hospitals and longer for stroke in minor teaching hospitals.. Major teaching hospital status was an important determinant of outcomes in patients hospitalized with myocardial infarction, heart failure, or stroke in New York State.

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Cardiovascular Diseases; Coronary Artery Bypass; Female; Heart Failure; Hospital Charges; Hospital Mortality; Hospitals, Teaching; Humans; Length of Stay; Male; Multivariate Analysis; Myocardial Infarction; New York; Outcome and Process Assessment, Health Care; Quality Indicators, Health Care; Stroke; Zimeldine

2002
Cardiovascular effects of amitriptyline, mianserin and zimelidine in depressed patients.
    Progress in neuro-psychopharmacology, 1980, Volume: 4, Issue:4-5

    Topics: Adult; Amitriptyline; Antidepressive Agents; Blood Pressure; Brompheniramine; Cardiovascular Diseases; Depressive Disorder; Dibenzazepines; Female; Heart Rate; Humans; Male; Mianserin; Myocardial Contraction; Pyridines; Zimeldine

1980